Sexual Dysfunction Linked To Antidepressant Use In Female Patients
According to a recent study conducted at the Postgraduate Institute of Medical Education and Research in Chandigarh, India, 42.5 percent of married female patients experience sexual dysfunction associated with antidepressant useI.
The study used a Female Sexual Function Index scale to assess the sexual function of eighty married female patients, all of which were diagnosed with a depressive disorder and were currently in remission and receiving a single antidepressant. Patients were asked to complete a 19-item self-report questionnaire, which targeted key dimensions of sexual functioning - desire, arousal, lubrication, orgasm, satisfaction, and pain - in addition to answering questions regarding their self-perceived sexual dysfunction.
Although the incidence and prevalence of sexual dysfunction vary depending on a number of factors, the general consensus is that 30-65% of patients experience sexual dysfunction while receiving selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and monoamine oxidase inhibitors. Sexual dysfunction can range from lack of desire to vaginal dryness and pain. Not only does this affect a women's physical wellbeing, but it also impacts their self-esteem and intimate relationships. In addition, patients who experience sexual dysfunction often discontinue their medication, jeopardizing their mental health.
Despite the known prevalence, sexual effects of antidepressant medication are often not addressed. To help moisturize and soothe the vulva, patients taking SSRI, SNRI and MAOI medications can use NeoGyn Vulvar Soothing Cream. The cream helps restore vulvar skin without estrogens. NeoGyn relies on a scientific formulation of cutaneous lysate, a novel ingredient discovered in Switzerland after years of wound healing research.